U.S. market Closed. Opens in 11 hours 39 minutes

TRDA | Entrada Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue129.01MN/AN/AN/AN/A
Cost of Revenue2.84M1.90M1.12M326.00K104.00K
Gross Profit126.17M-1.90M-1.12M-326.00K-104.00K
Operating Expenses129.33M97.25M51.13M26.67M11.82M
Selling, General & Admin32.29M30.64M15.20M5.57M3.61M
Research & Development97.04M66.61M35.93M21.10M8.22M
Other Operating ExpensesN/AN/AN/AN/A6.27M
Operating Income-3.16M-97.25M-51.13M-26.67M-11.82M
Other Expenses / Income15.22M2.63M-31.00K144.00K6.72M
Before Tax Income12.06M-94.62M-51.16M-26.52M-5.10M
Income Tax Expenses18.74M-7.16M-1.09M-144.00K-451.00K
Net Income-6.68M-87.46M-50.07M-26.38M-4.65M
Interest ExpensesN/A2.63M-31.00KN/AN/A
Basic Shares Outstanding33.05M31.29M31.22M31.25M31.25M
Diluted Shares Outstanding33.05M31.29M31.22M31.25M31.25M
EBITDA-321.00K-97.25M-51.13M-26.34M-11.72M
EBITDA Margin-0.25%0.00%0.00%0.00%0.00%
EBIT12.06M-91.98M-51.19M-26.52M-5.10M
EBIT Margin9.34%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙